Led · Equity · Mar 2026

Circadence develops AI-powered platforms that help organizations prepare for modern digital conflict through immersive training, threat simulation, and vulnerability discovery. Its new RangeGPT engine uses large language models to generate complex, real-world cyber environments in hours rather than months, enabling rapid digital twin creation and continuous resilience testing. Project Ares GEN3, built on cloud-native architecture, offers live-fire cyber training with integrated analytics that surface team readiness and performance gaps. Together, the products create mission-tailored scenarios on demand for cyber protection teams. The company reports strong revenue growth, expanding global contracts, and accelerating adoption across defense and enterprise markets. Management positions Circadence as a category-defining leader capable of outpacing legacy providers through its scalable AI architecture.

Led · Series B · Mar 2023

SolasCure is advancing Aurase Wound Gel, an investigational hydrogel formulation that contains tarumase (provisional INN), an enzyme cloned from medical maggots, for the treatment of chronic wounds. The company is in clinical development and has published Phase IIa trial data. Recent non-dilutive funding will be used to optimize the product for further clinical trials by improving ambient temperature stability and adjusting release kinetics so tarumase remains at optimal concentrations at the wound surface. SolasCure aims to deliver a cost-effective, fast, efficacious, and pain-free therapy usable in community and home care settings. The work targets a substantial unmet need: millions of patients worldwide with chronic wounds and a large associated healthcare and economic burden. Innovate UK’s award provides technical validation to support continued development. SolasCure is a Cambridge, England–based biotechnology company developing Aurase Wound Gel, a hydrogel containing a recombinant enzyme cloned from medical maggots intended to accelerate wound debridement. Pre-clinical results published in the International Wound Journal showed preliminary evidence supporting the enzymatic debridement approach and indicated a favorable local and systemic safety profile. The company completed a CLEANVLU first-in-man Phase IIa safety study in chronic venous leg ulcer subjects and is currently collating and analyzing those results. Aurase is due to enter further Phase II efficacy-supporting trials with larger and more diverse patient groups. SolasCure raised GBP 10.9m (approximately USD 13.3m) in a Series B to progress its clinical development and advance the product toward demonstrating efficacy. Founded in 2017 as a spin-off from BRAIN Biotech AG, the company has attracted industry veterans, institutional venture, and strategic investors. SolasCure's lead investigational product, Aurase Wound Gel, is a biologic combining an enzyme cloned from medical maggots with a hydrogel to perform wound debridement. The company progressed through an extensive preclinical research programme between 2018 and 2020. A first-in-human Phase IIa study has begun, with sites in the UK, US and Hungary. The trial is expected to yield results in 2022 and, if successful, the team plans to proceed to Phase IIb studies. SolasCure completed a Series A investment round totaling £15 million prior to initiating these clinical activities. The company reported making strong progress despite challenges posed by the COVID-19 pandemic. An IND for Aurase Wound Gel has been granted by the FDA, and the company has enrolled its first patients. SolasCure is developing proprietary technology that leverages biomimicry and evidence-based medicine to empower health care professionals to treat chronic wounds. Its first investigational product, Aurase®, is a hydrogel containing an enzyme cloned from medical maggots to support clinicians in wound care. The company raised £1.2m to advance development of Aurase®. The funding was provided by Seneca Partners via two vehicles. SolasCure is led by Dr. Sam Bakri, Executive Chairman and CEO. The article does not report operating metrics or other financings.

Participated · Equity · Feb 2023

Fabacus offers Xelacore, a SaaS platform and data service designed to digitally transform the licensing industry by bridging sales reporting and data flows between licensor, licensee and end-user. The platform aims to create a connected world of licensing through data, improving connectivity, visibility and trust across the value chain. Fabacus enables consumer engagement initiatives and provides data capture and structuring to help meet ESG reporting requirements. The company plans to use new funding to accelerate growth, expand operations and broaden its business reach. Customers include Epic Games, Ultimate Fighting Championship (UFC), Skydance Animation, Ubisoft and Activision Blizzard, and it has strategic partnerships with IMG Licensing, Fanatics and Wildbrain CPLG. The company is led by CEO and Founder Andrew Xeni and is based in London, UK.

Participated · Equity · Mar 2018

SuperCarers is a London-based online platform that connects people seeking at-home care with experienced, independent carers through a personalized matching process. The service tailors care to individual requirements and enables transparent charging, direct communication, and efficient care scheduling. Co-founded in 2014 by brothers Adam Pike (CEO) and Daniel Pike (Chief Commercial Officer), the company emphasizes matching and operational transparency. It raised new funding to support growth and product development. The company plans to use the capital to expand its business reach through marketing, develop its technology, and recruit people to support growth.

Participated · Equity · Jun 2015

My Parcel Delivery is an online courier comparison service that enables users to book and pay for parcel shipping from leading firms such as Parcelforce and City Link. Launched in 2010 by David Grimes and Paul Haydock, the Manchester-based company was ranked first in the Startups 100 in 2013. The My Parcel Delivery website has been growing at over 40% per year. The business has formed a parent company, MPD Group, to position its existing service alongside a new delivery-management SaaS product called Electio. The company plans to use the latest funding to support a complete group restructure and to develop and launch Electio, investing in technology and expertise as it diversifies into new markets.